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Objectives: This study evaluated the feasibility and outcomes of percutaneous transhepatic balloon angioplasty (PTBA) of
the hepatic vein in the management of Budd-Chiari syndrome (BCS) secondary to hepatic venous outflow obstruction.
Methods: From September 1996 to October 2008, 101 patients (52 males, 49 females) with BCS secondary to occlusion
of the hepatic veins were prospectively treated using PTBA of the hepatic vein. Average age was 31.3 years (range, 15-57
years). Nineteen had concurrent inferior vena cava (IVC) obstruction. All the patients presented with symptomatic portal
hypertension. PTBA, with or without stenting, was performed after hepatovenography.
Results: PTBAwas successfully performed in 92 of the 101 patients. Sixty-eight patients underwent PTBA of right hepatic
vein, followed by stent placement in two. PTBA was performed in 11 patients with left hepatic vein occlusion and in 13
patients with dominant accessory hepatic vein occlusion. The technical success rate was 92 of 101 (91%). Hepatic venous
pressure was significantly decreased after balloon angioplasty/stenting (P < .01, paired t test). Symptoms were
significantly improved in the 92 patients who had successful PTBA. Three patients had acute hepatic vein thrombosis
during or after PTBA. Two patients sustained intraperitoneal bleeding from the transhepatic puncture track, and one had
intrahepatic hematoma. Pulmonary embolism developed in one patient during the operation. All complications were
managed nonoperatively. There were no perioperative deaths. Within 1 year, 74 of the 101 patients returned for
follow-up, and 51 patients had follow-up at 2 years. The primary patency rates were 84% (62 of 74), 78% (58 of 74), and
76% (39 or 51) at 6, 12, and 24 months after PTBA, respectively. The secondary patency rates were 95% (70 of 74), 92%
(68 of 74), and 84% (43 of 51) at 6, 12, and 24 months.
Conclusions: PTBA of the hepatic vein is a safe and effective treatment of BCS. It is currently the most physiologic
procedure, and the risk of postoperative encephalopathy is minimized because portal flow is not diverted. Midterm
outcomes are satisfactory. Further investigation of the long-term outcomes is needed. (J Vasc Surg 2009;50:1079-84.)Budd-Chiari syndrome (BCS) is an uncommon condi-
tion characterized by hepatic venous outflow obstruc-
tion.1,2 The obstruction may be caused by thrombosis,
extrinsic compression, membranous webs, or postoperative
complications after liver transplantation. Thrombus is the
most frequent cause in Western countries, and membra-
nous webs are more common in Asia.3
Various treatments have been described, including an-
ticoagulation, percutaneous balloon angioplasty with or
without stenting, transjugular intrahepatic portosystemic
shunt (TIPS), surgical shunts, and liver transplantation.
However, only small series of patients treated with percu-
taneous transhepatic balloon angioplasty (PTBA) have
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doi:10.1016/j.jvs.2009.06.049been published due to the rarity of BCS.3,4,5,11 We present
the results of a clinical study of PTBA in the treatment of
101 patients with BCS.
MATERIAL AND METHODS
From September 1996 to October 2008, 101 patients
(52 males, 49 females) with symptomatic BCS due to
hepatic vein occlusion, with or without inferior vena cava
(IVC) obstruction, were treated with PTBA at the People’s
Hospital of Henan Province, China. This clinical study was
approved by the Committee of Medical Affairs of People’s
Hospital of Henan Province.
Themedical records of the patients were retrospectively
reviewed. The 101 patients presented with secondary portal
hypertension for 3 to 156 months. Common clinical pre-
sentations are stomach bloating, abdominal pain, upper
gastrointestinal bleeding, jaundice, hepatomegaly, and as-
cites (Table I). Patients were a mean age of 31.3 years
(range, 15-57 years).
Of the 101 patients, 51 (50%) had occlusion in all three
hepatic veins (right, middle, and left), 35 (35%) had disease
in two veins, and 11 (11%) had single vein involvement.
Thirteen (13%) had occlusion in dominant accessory he-
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occlusion in all the hepatic veins and branches. Right
hepatic vein obstruction was found 82% (83 of 101), fol-
lowed by middle in 50% and left hepatic veins in 41%. In 19
patients, hepatic vein occlusion was combined with IVC
stenosis.
Procedure techniques
Percutaneous transhepatic venography. Under flu-
oroscopic guidance, a 21-gauge Chiba needle with syringe
is inserted through the eighth or ninth intercostals space on
the midaxillary line. Negative pressure is applied on the
syringe while the needle is slowly advanced in the direction
toward the xiphoid. After blood return, a small amount of
contrast is injected. When the entrance of right hepatic vein
is confirmed, a 0.018-inch guidewire is placed and the
needle is removed. A 4F angiocatheter is then inserted into
Fig 1. Percutaneous transhepatic venography demonstrates oc-
clusion of the hepatic venous outflow.
Table I. Comparison of clinical presentations before and






6 mon 12 mon 24 mon
(n  74) (n  74) (n  51)
Stomach bloating 79 (78) 8 (11) 8 (11) 7 (14)
Abdominal pain 34 (34) 4 (5) 3 (4) 2 (4)
Upper GI bleeding 13 (13) 0 0 0
Jaundice 11 (11) 0 0 1 (2)
Hepatomegaly 79 (78) 8 (11) 4 (5) 4 (8)
Ascites 58 (57) 3 (4) 5 (7) 5 (10%)
GI, Gastrointestinal; PTBA, percutaneous transhepatic balloon angioplasty.the right hepatic vein over the guidewire. Percutaneoustranshepatic venography is performed by injecting intrave-
nous contrast through the catheter (Fig 1). The same
technique is used for the left hepatic venography, but the
puncture site is usually 2 to 3 cm below the xiphoid.
Hepatic venous pressure is measured through the side port
of the introducer sheath and recorded as cm H2O.
Traversing obstruction. After hepatic venography,
Fig 2. A, Percutaneous transhepatic venography shows occlusion
of the right hepatic vein. B, The occlusive lesion is successfully
traversed under fluoroscopic guidance with roadmap.heparin is given intravenously at 50 IU/kg. A 0.035-inch
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and a 7F introducer sheath is inserted over the wire after the
angiocatheter is removed. To cross the occlusive lesion, we
use a 0.035-inch Glidewire (Boston Scientific, Natick,
Mass) and a 4FHeadhunter catheter (Cook, Bloomington,
Ind).
The Glidewire can easily pass through partial occlusive
lesions. For the membranous or segmental obstructive
Fig 3. A-D, The patient presented with symptomatic
Percutaneous transhepatic balloon angioplasty was perfor
angioplasty.lesions, we advance Headhunter catheter against the stumpof the hepatic vein, then push and spin the Glidewire while
advancing. If this technique fails, the stiff back end of the
Glidewire can be used under the guidance of continuous
fluoroscopy with roadmap. The stiff end of the glidewire
should be advanced slowly and with 3 mm each move-
ment. We successfully crossed 24 complete occlusive le-
sions in our group using this technique (Fig 2).
Balloon angioplasty and stenting. After the obstruc-
-Chiari syndrome secondary to hepatic vein occlusion.
and the right hepatic vein was widely patent after balloonBudd
medtion is transversed, the Glidewire is switched to a stiff wire.
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is performed till the waist disappears and remains for 2
minutes (Fig 3). Noncompliant balloons from 12 to 16mm
in diameter are used according to the sizes of hepatic veins.
If a follow-up angiogram shows significant residual stenosis
or recoiling after 15 minutes, a stent should be placed. Two
patients in our group required stenting, and one 12- 
40-mm Wallstent (Boston Scientific) was placed in each.
Angioplasty is with a large balloon in patients with com-
bined IVC stenosis.
At the end of procedure, the introducer sheath is with-
drawn into hepatic parenchyma. Gelfoam strips are pushed
into the intrahepatic puncture track using inner dilator of
the introducer sheath while the sheath is slowly pulled out.
Patients were treated postoperatively with heparin drips
and discharged home with oral warfarin for 6 months.
RESULTS
PTBA was successful in 92 of the 101 patients (91%).
Venography demonstrated significant improvement of the
hepatic venous outflow after balloon angioplasty. Free he-
patic vein pressure (FHVP) was measured before and after
PTBA. Hepatic venous pressures before and after PTBA
were decreased in each patient. Mean pressure drops in this
group were statistically significant after balloon angioplasty
(Table II). Symptoms were significantly improved in the 92
patients who had successful PTBA. There were no periop-
erative deaths.
Technique failure occurred in nine patients (9%). In
four patients the long segmental occlusive lesions could not
be crossed with different catheters and wires. The other
four patients had diffused hepatic venous stenoses that were
unsuitable for endovascular intervention due to lack of
target veins. A large thrombus developed in one patient
during the operation and the procedure was aborted. The
nine patients with technical failure were referred to surgery
for an open shunt.
One patient sustained pulmonary embolization during
balloon angioplasty and was successfully managed conser-
vatively. Postoperatively, two patients had intraperitoneal
bleeding and intrahepatic hematoma developed in one.
Anticoagulationwas temporarily held andbleeding stopped in
Table II. Comparison of free hepatic venous pressure




PNo. Mean  SD Mean  SD
Hepatic vein
Right 68 48  13 9  5 .01
Left 11 56  16 12  6 .01
Accessory 13 51  19 9  8 .01
Mean FHVP 92 55  18 11  5 .01
FVHP, Free hepatic venous pressure; PTBA, percutaneous transhepatic
balloon angioplasty; SD, standard deviation.all three patients without surgical intervention.All of the patients in whom PTBA was successful un-
derwent a baseline duplex ultrasound examination before
discharge. Postoperative follow-up at 6, 12, and 24months
showed that primary patency rates were 84%, 78%, and
76%, respectively (Fig 4). In 12 patients (12%), redo PTBA
was required for recurrent symptoms24 months and was
successful in all. The secondary patency rates were 95%,
92%, and 84% at 6, 12, and 24 months. Clinical presenta-
tions (Table I) and liver functions (Table III) were im-
proved in most patients who had successful PTBA. Asymp-
tomatic patients with hepatic vein restenosis after PTBA
were managed with anticoagulation and follow-up ultra-
sound imaging.
Univariate and multivariate analysis demonstrated that
long segmental stenosis or occlusion is a risk factor for
post-PTBA hepatic venous restenosis. Sex, age, history of
hepatitis, liver function, and clinical presentations at admis-
sion are not associated with the patency of the hepatic veins
after PTBA.
DISCUSSION
BCS is a complex disorder characterized by hepatic
venous outflow obstruction that may be located from small
hepatic veins to the atriocaval junction. Obstruction is
usually caused by thrombosis of hepatic veins, membranous
webs within hepatic vein or IVC, or both, extrinsic com-
pression from tumor or cyst, or postoperative complica-
tions after liver transplantation.2,3,5-7 Thrombosis is the
most frequent cause in Western countries,3 while membra-
nous webs is more common in Asia.8 BCS may also be
multifactorial in some patients.9 Patients with BCS may
present with hepatomegaly, right upper quadrant pain,
ascites, or be asymptomatic.10 The natural history of BCS is
poorly understood. Prognosis is usually dismal if the disease
is left untreated.
Owing to the rarity of BCS, no controlled prospective
study has been performed. The management modalities
that have been published include anticoagulation and treat-
ment of underlying diseases, percutaneous transhepatic
balloon angioplasty with or without stenting, TIPS, surgi-
cal shunts, and liver transplantation.3,4,5,11
Medical treatment with anticoagulation, diuretic ther-
apy, and periodic paracentesis is associated with poor ou-
comes.12,13 Plessier et al13 reported that 20% of the
patients with BCS were successfully treated with conserva-
tive management alone. The use of a surgical portosystemic
shunt in the treatment of BCS is debated because periop-
erative mortality has been documented up to 50%.2,14,15
Therefore, open shunting procedures have been almost
abandoned as an option for the treatment of BCS in Eu-
rope.16 Liver transplantation should be reserved for pa-
tients with presentations of fulminant hepatic failure and
end-stage chronic cirrhosis.5
Percutaneous endovascular intervention has been in-
creasing in the treatment of BCS in recent years. Restora-
tion of good outflow in one of the three main hepatic veins
is usually adequate to resolve BCS symptoms.4,5,11 A ret-
rospective review demonstrated that the mortality rates
rd er
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intervention vs 44% (8 of 18) in the open shunting group.17
However, reocclusion rates are higher after percutaneous
endovascular procedures.4,5
In 1993 the first report of TIPS for the treatment of
BCS was published.5 This procedure can effectively de-
compress the portal venous system and significantly im-
prove the symptoms in patients with BCS. Currently,
TIPS has been used as the first choice of BCS treatment
in most insititutions.18 Stent misplacement or migration
during or after TIPS procedure is not uncommon, how-
ever.8,19
Eapen et al11 stated that TIPS was technically more
difficult in BCS treatment, and reocclusion was more com-
mon due to the increased thrombotic tendency and longer
shunt requirement in the BCS group than in other patients.
Hepatic encephalopathy after TIPS is another major com-
plication. Hepatic encephalopathy occurred in 17% of
the BCS patients who underwent TIPS.11 In the patients
Variabl






















Survival Function of C
Fig 4. Cox Hazard modeling analysis shows the paten
angioplasty (PTBA). CI, Confidence interval; SE, standa
Table III. Liver function changes (Child-Pugh) after
percutaneous transhepatic balloon angioplasty
Child-Pugh class Pre-PTBA
Post-PTBA
6 mon 12 mon 24 mon
A 21 41 52 42
B 53 33 22 9
C 0 0 0 0
Patients, total 74 74 74 51
PTBA, Percutaneous transhepatic balloon angioplasty.presenting with encephalopathy, the outcomes of TIPSwere even worse. One of their three patients with en-
cephalopathy at presentation died shortly after TIPS
procedure.
As the most physiologic technique restoring hepatic
venous outflow,4,11 percutaneous hepatic vein balloon an-
gioplasty through the internal jugular vein, femoral vein,
or the transhepatic approach has become more attrac-
tive.3,4,5,11 PTBA of hepatic veins was successfully per-
formed in 92 of our 101 patients, and the rates of postpro-
cedural encephalopathy and death were zero. Our study
also showed favorable midterm outcomes, with a primary
patency of 76% and secondary patency of 84% at the 2-year
follow-up.
Using percutaneous hepatic vein revascularization
as the first choice of BCS treatment has been recom-
mended.3,4,5,11 Most percutaneous intervention proce-
dures are performed through transjugular or femoral
approaches. Although a percutaneous transhepatic ap-
proach has been reported,11,20 bleeding from the punc-
ture track has been a major concern. A combined tran-
sjugular and percutaneous transhepatic technique avoids
a large puncture track in the liver.11 The procedure is
more challenging, however, with prolonged radiation
and operation time.
To prevent bleeding from the puncture track after
transhepatic intervention, we routinely insert Gelfoam
strips through the introducer sheath while it is slowly
being pulled out. The puncture track is sealed at the end
of the procedures. Only 3.3% of our patients (3 of 92)
had perihepatic hematoma or intraperitoneal bleeding
after PTBA, and all were successfully managed conserva-
the Equation
.027 .974 .951 .997
Sig. Exp(B) Lower Upper
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60050000
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PTBA is currently the most physiologic modality for
the treatment of BCS. The technical success rate of PTBA
is 90%. Post-PTBA hepatic encephalopathy is minimized
because there is no diversion of portal flow compared with
shunt procedures such as TIPS. Packing of the transhepatic
puncture track with Gelfoam strips may effectively prevent
postoperative bleeding. Our experience demonstrated that
PTBA is effective and safe, with satisfactory midterm out-
comes in the treatment of BCS. Long-term follow-up is
needed.
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